Stemtech (STEK) EBITDA Margin (2021 - 2025)

Stemtech has disclosed EBITDA Margin across 5 years of filings, most recently posting 275.55% for Q4 2025.

• EBITDA Margin for Q4 2025 came in at 275.55%, down 30340.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 61.66% (up 3446.0% YoY), and the FY2025 annual result was 140.46%, down 5921.0% from the prior year.
• EBITDA Margin came in at 275.55% for Q4 2025 at Stemtech, down from 14.91% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1624.65% in Q3 2022 to a low of 1925.71% in Q2 2022.
• The 5-year median for EBITDA Margin is 54.38% (2022), against an average of 113.04%.
• Peak annual rise in EBITDA Margin reached 226213 bps in 2022, while the deepest fall reached 189688 bps in 2022.
• Stemtech's EBITDA Margin stood at 44.53% in 2021, then surged by 81 bps to 8.59% in 2022, then tumbled by 938 bps to 89.08% in 2023, then soared by 131 bps to 27.85% in 2024, then sank by 1089 bps to 275.55% in 2025.
• The last three EBITDA Margin figures came in at 275.55% (Q4 2025), 14.91% (Q3 2025), and 55.76% (Q2 2025), per Business Quant data.